• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viruses. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs

tetano

Editor, Senior Moderator
Viruses. 2020 Apr 14;12(4). pii: E445. doi: 10.3390/v12040445.
Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.


Calligari P[SUP]1[/SUP], Bobone S[SUP]1[/SUP], Ricci G[SUP]1[/SUP], Bocedi A[SUP]1[/SUP].

Author information




Abstract

A new Coronavirus strain, named SARS-CoV-2, suddenly emerged in early December 2019. SARS-CoV-2 resulted in being dramatically infectious, with thousands of people infected. In this scenario, and without effective vaccines available, the importance of an immediate tool to support patients and against viral diffusion becomes evident. In this study, we exploit the molecular docking approach to analyze the affinity between different viral proteins and several inhibitors, originally developed for other viral infections. Our data show that, in some cases, a relevant binding can be detected. These findings support the hypothesis to develop new antiviral agents against COVID-19, on the basis of already established therapies.



KEYWORDS:

COVID-19; RNA-dependent RNA-polymerase; SARS–CoV-2; antiviral drug; coronavirus; molecular docking; molecular modeling; spike protein; viral protease; viral protein N


PMID:32295237DOI:10.3390/v12040445
Free full text
 
Back
Top Bottom